NASDAQ:TECH - Nasdaq - US09073M1045 - Common Stock - Currency: USD
BIO-TECHNE CORP
NASDAQ:TECH (1/23/2025, 6:39:42 PM)
After market: 78.56 +1.65 (+2.15%)76.91
-1.8 (-2.29%)
The current stock price of TECH is 76.91 USD. In the past month the price increased by 5.11%. In the past year, price increased by 5.89%.
These S&P500 stocks are moving in today's session
What's going on in today's session: S&P500 movers
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Thursday. Discover the gap up and gap down stocks in the S&P500 index.
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, February 5, 2025,...
/PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that BrainChild Bio has been...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 26.82 | 219.88B | ||
DHR | DANAHER CORP | 33.02 | 177.44B | ||
A | AGILENT TECHNOLOGIES INC | 28.82 | 43.48B | ||
IQV | IQVIA HOLDINGS INC | 18.97 | 37.39B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 35 | 28.17B | ||
WST | WEST PHARMACEUTICAL SERVICES | 50.89 | 24.91B | ||
WAT | WATERS CORP | 36.24 | 24.51B | ||
ILMN | ILLUMINA INC | 77.9 | 21.37B | ||
ICLR | ICON PLC | 14.45 | 16.73B | ||
RVTY | REVVITY INC | 26.01 | 14.97B | ||
AVTR | AVANTOR INC | 22.32 | 14.88B | ||
MEDP | MEDPACE HOLDINGS INC | 30.46 | 10.81B |
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. The company is headquartered in Minneapolis, Minnesota and currently employs 3,100 full-time employees. The firm's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.
BIO-TECHNE CORP
614 Mckinley Pl N E
Minneapolis MINNESOTA 55413 US
CEO: Charles Kummeth
Employees: 3100
Company Website: https://www.bio-techne.com/
Investor Relations: https://investors.bio-techne.com/
Phone: 16123798854
The current price of TECH is 76.91 USD.
The exchange symbol of BIO-TECHNE CORP is TECH and it is listed on the Nasdaq exchange.
TECH is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for TECH, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of TECH.
TECH has a dividend yield of 0.42%. The yearly dividend amount is currently 0.32.
TECH will report earnings on 2025-02-04, after the market close.
The PE ratio for TECH is 42.97. This is based on the reported non-GAAP earnings per share of 1.79 and the current share price of 76.91 USD.
The outstanding short interest for TECH is 2.4% of its float.
ChartMill assigns a technical rating of 6 / 10 to TECH. When comparing the yearly performance of all stocks, TECH turns out to be only a medium performer in the overall market: it outperformed 64.97% of all stocks.
ChartMill assigns a fundamental rating of 7 / 10 to TECH. TECH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
Over the last trailing twelve months TECH reported a non-GAAP Earnings per Share(EPS) of 1.79. The EPS increased by -8.67% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 13.92% | ||
ROA | 7.37% | ||
ROE | 9.43% | ||
Debt/Equity | 0.14 |
ChartMill assigns a Buy % Consensus number of 83% to TECH. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of 9.84% and a revenue growth 5.58% for TECH